141 related articles for article (PubMed ID: 37974941)
21. Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.
Maddeboina K; Jonnalagadda SK; Morsy A; Duan L; Chhonker YS; Murry DJ; Penning TM; Trippier PC
J Med Chem; 2023 Jul; 66(14):9894-9915. PubMed ID: 37428858
[TBL] [Abstract][Full Text] [Related]
22. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
[TBL] [Abstract][Full Text] [Related]
23. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
24.
Mowday AM; Copp JN; Syddall SP; Dubois LJ; Wang J; Lieuwes NG; Biemans R; Ashoorzadeh A; Abbattista MR; Williams EM; Guise CP; Lambin P; Ackerley DF; Smaill JB; Theys J; Patterson AV
Theranostics; 2020; 10(23):10548-10562. PubMed ID: 32929365
[TBL] [Abstract][Full Text] [Related]
25. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Chen L; Waxman DJ
Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
[TBL] [Abstract][Full Text] [Related]
26. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
27. Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
van der Wiel AMA; Jackson-Patel V; Niemans R; Yaromina A; Liu E; Marcus D; Mowday AM; Lieuwes NG; Biemans R; Lin X; Fu Z; Kumara S; Jochems A; Ashoorzadeh A; Anderson RF; Hicks KO; Bull MR; Abbattista MR; Guise CP; Deschoemaeker S; Thiolloy S; Heyerick A; Solivio MJ; Balbo S; Smaill JB; Theys J; Dubois LJ; Patterson AV; Lambin P
Mol Cancer Ther; 2021 Dec; 20(12):2372-2383. PubMed ID: 34625504
[TBL] [Abstract][Full Text] [Related]
28. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
30. Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
Jackson-Patel V; Liu E; Bull MR; Ashoorzadeh A; Bogle G; Wolfram A; Hicks KO; Smaill JB; Patterson AV
Front Pharmacol; 2022; 13():803602. PubMed ID: 35211015
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
Jameson MB; Rischin D; Pegram M; Gutheil J; Patterson AV; Denny WA; Wilson WR
Cancer Chemother Pharmacol; 2010 Mar; 65(4):791-801. PubMed ID: 20012293
[TBL] [Abstract][Full Text] [Related]
32. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
33. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
34. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
35. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Guise CP; Abbattista MR; Tipparaju SR; Lambie NK; Su J; Li D; Wilson WR; Dachs GU; Patterson AV
Mol Pharmacol; 2012 Jan; 81(1):31-40. PubMed ID: 21984255
[TBL] [Abstract][Full Text] [Related]
36. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
[TBL] [Abstract][Full Text] [Related]
37. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
39. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Evans K; Duan J; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB
Clin Cancer Res; 2019 Jul; 25(14):4493-4503. PubMed ID: 31015346
[TBL] [Abstract][Full Text] [Related]
40. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]